It is vital that health care professionals managing patients with growth disorders are knowledgeable of the emerging advances in treatments for these conditions, most notably growth hormone therapy. This monograph will review the molecular mechanism of growth hormone signaling, its multiple sites of action, and the complex pathways by which this peptide hormone is regulated. The genetic defects that result in growth hormone deficiency will be presented, as well as the pathophysiology of this disorder. Criteria for the diagnosis of short stature and the management of growth hormone deficiency with growth hormone therapy will be evaluated.
Cardiovascular disease accounts for a majority of deaths in patients with type 2 diabetes. According to the World Health Organization, the prevalence of cardiovascular disease in diabetic patients ranges from 26% to 36%. Within the last decade, newly available treatments have created an opportunity to better achieve glycemic goals and improve the management of concomitant cardiovascular disease and diabetes. This symposium aims to update you on emerging concepts for reducing cardiovascular disease risk in your patients with diabetes. An expert faculty chaired by Robert Eckel, MD, will present the latest clinical concepts in glycemic control and CVD risk. Engaging panel discussions will guide you in applying these concepts directly to your practice.
